Ultrastructural features and clinical significance of autophagosome in benign meningiomas

doi:10.12307/2023.752

Abstract

Abstract: BACKGROUND: Meningiomas are one of the most common benign tumors in the intracranial field, and clinical treatment is mainly surgery. However, the postoperative recurrence rate is high, and other treatment modalities do not yet have a definite effect, so the exploration of new targeted drugs is promising for meningioma treatment. At present, the pathogenesis of autophagy in benign meningiomas is not very clear, and a large number of experiments are still needed for in-depth study.
OBJECTIVE: To investigate the ultrastructural features and clinical significance of autophagy in benign meningiomas.
METHODS: Meningiomas were diagnosed by light microscopy with different subtyping. Diagnosis and typing of meningiomas were aided by transmission electron microscopy, and the ultrastructural morphology and number of autophagosomes in the cytoplasm of meningioma cells of different grades were observed. Western blot assay was used to detect the expression levels of autophagy-related proteins Beclin1 and LC3 in different grades of meningiomas. The altered expression of Vimentin, EMA, PR, S-100 and GFAP in meningiomas was evaluated by immunohistochemical staining.
RESULTS AND CONCLUSION: 176 meningiomas were identified, including 98 males and 78 females. (1) Histopathological types CNS WHO grade 1 benign meningiomas comprised a total of 168 cases, including 62 cases of meningocortical type, 36 cases of fibrous type, 58 cases of transitional type, 12 cases of angiomatous type, 4 cases of CNS WHO grade 2 clear cell type, 2 cases of atypical type, and 2 cases of WHO grade 3 anaplastic lesions. (2) Transmission electron microscopy revealed autophagic bodies in 27 cases of WHO grade 1 meningiomas, and no autophagic bodies were detected in WHO grades 2 and 3 meningiomas. (3) LC3 and Beclin1 were highly expressed in WHO grade 1 benign meningiomas by western blot assay and were negatively expressed in WHO grades 2 and 3 meningiomas. (4) The immunohistochemical markers Vimentin, EMA, and PR, were expressed to various degrees, while GFAP and S-100 were negative. (5) A combination of electron microscopy, immunohistochemical staining and western blot assay showed that autophagy only plays an important role in the occurrence and development of WHO grade 1 benign meningiomas.

Key words: benign meningioma, autophagosome, ultrastructure, clinical significance, autophagy-related protein, LC3, Beclin1

CLC Number:

Zhang Qi, Li Guilin, He Yanjiao. Ultrastructural features and clinical significance of autophagosome in benign meningiomas[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(33): 5304-5308.

Figures/Tables 8

References

[1] GRITSCH S, BATCHELOR TT, GONZALEZ CASTRO LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2022;128(1):47-58.
[2] GONDAR R, PATET G, SCHALLER K, et al. Meningiomas and Cognitive Impairment after Treatment: A Systematic and Narrative Review. Cancers (Basel). 2021;13(8): 1846.
[3] CORNIOLA MV, MELING TR. Management of Recurrent Meningiomas: State of the Art and Perspectives. Cancers (Basel). 2022;14(16):3995.
[4] LI X, HE S, MA B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19(1):12.
[5] ANTUNES F, ERUSTES AG, COSTA AJ, et al. Autophagy and intermittent fasting: the connection for cancer therapy? Clinics (Sao Paulo). 2018;73(suppl 1):e814s.
[6] USMAN RM, RAZZAQ F, AKBAR A, et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. Asia Pac J Clin Oncol. 2021;17(3):193-208.
[7] FENG X, ZHANG H, MENG L, et al. Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5. Autophagy. 2021;17(3):723-742.
[8] WHITE E. The role for autophagy in cancer. J Clin Invest. 2015;125(1):42-46.
[9] ZAMAME RAMIREZ JA, ROMAGNOLI GG, KANENO R. Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy. Life Sci. 2021;265:118745.
[10] LIU W, MENG Y, ZONG C, et al. Autophagy and Tumorigenesis. Adv Exp Med Biol. 2020;1207:275-299.
[11] WANG Y, DU J, WU X, et al. Crosstalk between autophagy and microbiota in cancer progression. Mol Cancer. 2021;20(1):163.
[12] PARK S, CHA YJ, SUH SH, et al. Risk group-adapted adjuvant radiotherapy for WHO grade I and II skull base meningioma. J Cancer Res Clin Oncol. 2019;145(5): 1351-1360.
[13] MAGGIO I, FRANCESCHI E, TOSONI A, et al. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol. 2021; 10(2):CNS72.
[14] HORBINSKI C, BERGER T, PACKER RJ, et al. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol. 2022;18(9):515-529.
[15] PREUSSER M, BRASTIANOS PK, MAWRIN C. Advances in meningioma genetics: novel therapeutic opportunities. Nat Rev Neurol. 2018;14(2):106-115.
[16] KLIONSKY DJ, PETRONI G, AMARAVADI RK, et al. Autophagy in major human diseases. EMBO J. 2021;40(19):e108863.
[17] CHEN X, YU C, KANG R, et al. Cellular degradation systems in ferroptosis. Cell Death Differ. 2021;28(4):1135-1148.
[18] LI W, HE P, HUANG Y, et al. Selective autophagy of intracellular organelles: recent research advances. Theranostics. 2021;11(1):222-256.
[19] CAO W, LI J, YANG K, et al. An overview of autophagy: Mechanism, regulation and research progress. Bull Cancer. 2021;108(3):304-322.
[20] ONORATI AV, DYCZYNSKI M, OJHA R, et al. Targeting autophagy in cancer. Cancer. 2018;124(16):3307-3318.
[21] YANG K, NIU L, BAI Y, et al. Glioblastoma: Targeting the autophagy in tumorigenesis. Brain Res Bull. 2019;153:334-340.
[22] YAMAZAKI T, BRAVO-SAN PEDRO JM, GALLUZZI L, et al. Autophagy in the cancer-immunity dialogue. Adv Drug Deliv Rev. 2021;169:40-50.
[23] XU Z, HAN X, OU D, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol. 2020;104(2):575-587.
[24] SMITH AG, MACLEOD KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247(5):708-718.
[25] COCCO S, LEONE A, PIEZZO M, et al. Targeting Autophagy in Breast Cancer. Int J Mol Sci. 2020 22;21(21):7836.
[26] 曲宝清,米蕊芳,杜江,等. 脑胶质瘤超微结构及组织形态观察39例[J].中国临床医生杂志,2019,47(5):63-65.
[27] KOUSTAS E, SARANTIS P, THEOHARIS S, et al. Autophagy-related Proteins as a Prognostic Factor of Patients With Colorectal Cancer. Am J Clin Oncol. 2019; 42(10):767-776.
[28] ROY BC, AHMED I, RAMALINGAM S, et al. Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1’s elimination during colon cancer development and progression. Oncotarget. 2019;10(24):2340-2354.
[29] TOTON E, LISIAK N, SAWICKA P, et al. Beclin-1 and its role as a target for anticancer therapy. J Physiol Pharmacol. 2014;65(4):459-467.
[30] HAMURCU Z, DELIBAŞI N, GEÇENE S, et al. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells. J Cancer Res Clin Oncol. 2018;144(3):415-430.
[31] HU Y, LI X, XUE W, et al. TP53INP2-related basal autophagy is involved in the growth and malignant progression in human liposarcoma cells. Biomed Pharmacother. 2017;88:562-568.
[32] YING H, QU D, LIU C, et al. Chemoresistance is associated with Beclin-1 and PTEN expression in epithelial ovarian cancers. Oncol Lett. 2015;9(4):1759-1763.
[33] WANG L, WANG J, XIONG H, et al. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer. EBioMedicine. 2016; 7:50-61.
[34] ABDELZAHER E, EL-GENDI SM, YEHYA A, et al. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg. 2011;25(6):707-713.
[35] DOMINGUES PH, SOUSA P, OTERO Á, et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol. 2014;16(5):735-747.
[36] FOLKERTS H, HILGENDORF S, VELLENGA E, et al. The multifaceted role of autophagy in cancer and the microenvironment. Med Res Rev. 2019;39(2):517-560.